This article is more than 5 years old. Information may no longer be current.
Retinal sensitivity in DME improves with anti-VEGF
MIAMI — Aflibercept improves retinal sensitivity better than laser photocoagulation in patients with diabetic macular edema, a speaker said here.
According to Diana V. Do, MD, Eylea (aflibercept, Regeneron) was shown to improve retinal sensitivity in a substudy of the DA VINCI trial.
Visual acuity benefits were sustained through 1 year of treatment. On average, eyes that received aflibercept gained 9.7 to 13.1 letters of visual acuity, compared with a loss of one letter in the laser treatment group, Do said at Angiogenesis, Exudation, and Degeneration 2013.
On average, eyes that received aflibercept gained 1 dB to 4 dB of retinal sensitivity, compared with a gain of approximately 1 dB in the laser treatment group.
Due to the positive visual acuity results obtained in the phase 2 DA VINCI study, two phase 3 clinical trials, VIVID and VISTA, are currently under way to further investigate treating diabetic macular edema with aflibercept, Do said.
Disclosure: Do receives research support from Regeneron and Genentech.